Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Brief Summary: The purpose of this study is to assess the efficacy and safety of LY2189265 in comparison to Insulin Glargine, both in combination with Insulin Lispro (plus or minus Metformin), in participants with Type 2 Diabetes treated with 1 or 2 injections of insulin.


Options:
A: Inclusion Criteria:

* Not currently on drug therapy for type 2 diabetes
* Blood glucose criteria must be met
* Body mass index (BMI) in the range 22-45

Exclusion Criteria:

* History of type 1 diabetes
* Evidence of significant diabetic complications
* Serious cardiovascular events within the past 6 months
* Laboratory value abnormalities as defined by the protocol
* Other protocol-defined exclusion criteria may apply
B: Inclusion Criteria:

* Men and women ≥18 years old
* T2D (according to World Health Organization (WHO) criteria) of less than 4 years duration
* BMI 18.5-45 kg/m2
* Drug naïve or oral monotherapy with glucose-lowering drug.
* Accepting NDR participation and other register data collection.

Exclusion Criteria:

* Known or suspected other form of diabetes than type 2
* Ongoing or more than \>4 weeks in total of any previous treatment with: insulin, GLP-1 receptor agonists, SGLT2 inhibitors or combination of any diabetes medications
* Medical need to start or intensify any specific GLD treatment, e.g. insulin due to marked hyperglycemia
* HbA1c \>70 mmol/mol for patients on monotherapy, \>80 in drug naïve
* Contraindication to either metformin or dapagliflozin, or any unacceptable risk with either treatment as assessed by the investigator
* History or signs of established cardiovascular disease: diagnosis of myocardial infarction, angina pectoris, heart failure, stroke, lower extremity arterial disease, any limb amputation (except due to trauma or malignancy)
* Any serious illness or other condition with short life expectancy (\<4 yr)
* Renal impairment (eGFR \<60 ml/min/1,73m2)
* Any condition, as judged by the investigator, that suggests that the patient will be non-compliant or otherwise unsuitable to study medication or study participation
* Pregnancy or breastfeeding, women of childbearing potential (WOCBP; including perimenopausal women who have had a menstrual period within 1 year) without adequate anticonception during any part of the study period
* Involvement in the planning and/or conduct of the study
* Ongoing participation in another clinical trial.
C: Inclusion Criteria:

* Type 2 diabetes
* Currently using insulin for at least 3 months with a conventional insulin regimen with or without oral medications
* Glycosylated hemoglobin (HbA1c) greater than or equal to 7% and less than or equal to 11%
* Willing to inject subcutaneous medication
* Willing to monitor blood glucose levels and adjust insulin dose
* Willing to maintain a study diary
* Body mass index (BMI) between 23 and 45 kilograms per square meter (kg/m\^2)
* Stable weight for 3 months prior to screening
* Females of child bearing potential must test negative for pregnancy at screening and be willing to use a reliable method of birth control during the study and for 1 month following the last dose of study drug

Exclusion Criteria:

* Type 1 Diabetes
* Previous therapy with glucagon-like peptide 1 (GLP-1) agonists within 3 months prior to screening
* 1 or more episodes of ketoacidosis within 6 months prior to screening
* Have been treated with prescription or over the counter medication to promote weight loss within 3 months prior to screening
* Estimated glomerular filtration rate (eGFR) less than or equal to 30 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2) at screening
* Taking steroids for greater than 14 days except for topical, eye, nasal, or inhaled
* History of heart failure, New York Heart Classification III or IV within 2 months prior to screening
* Gastrointestinal (GI) problems such as diabetic gastroparesis or bariatric surgery (stomach stapling) or chronically taking medications that directly affect GI motility
* Acute or chronic hepatitis or pancreatitis
* Self or family history of 2A or type 2B multiple endocrine neoplasia or medullary C-Cell hyperplasia
* Serum calcitonin greater than or equal to 20 picograms per milliliter (pcg/mL) at screening
* Organ transplant except cornea
* Significant active autoimmune disease such as Lupus or Rheumatoid Arthritis
* History of or active malignancy except skin or in situ cervical or prostate cancer within the last 5 years
* Known drug or alcohol abuse
* Have enrolled in another clinical trial within the last 30 days
* Have previously signed an informed consent or participated in a LY2189265 study
D: Inclusion Criteria:

* Coronary heart disease
* Type 2 diabetes

Exclusion Criteria:

* Severe organ dysfunction, psychopathy, infection, neutropenia
* Congenital heart disease, rheumatic heart disease, severe arrhythmia, myocardiopathy

Answer: C